US.VTRS · Viatris

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.019675925925926,
        "turnoverUsdM": 136.66434048000002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VTRS",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 16.2364,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 6,
      "take_profit_price": 18.5358,
      "target_multiplier": 1.9,
      "technical_strength": 1.9,
      "take_profit_percent": 7.3
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2087389804522806,
    "stopLossPercent": 6.039351851851852,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 58.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 55.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 16.6645,
    "ma50": 16.3782,
    "close": 17.28,
    "prevClose": 17.01,
    "avgVolume20": 9571721,
    "volumeRatio": 0.83,
    "changePercent": 1.59
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.0028851702250430877,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.821138074636117,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0617211325640836,
      "volat_points": 0,
      "day_range_pct": 0.030381944444444565,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 58.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 8.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 56,
        "contribution": 8.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 22.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 76,
        "contribution": 22.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 55.8,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 8.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 22.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 10,
      "市場環境": 8.4,
      "情緒分析": 4,
      "技術信號": 22.8,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 136.66434048000002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VTRS",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.64
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 713.3184992500002,
                "ma50": 718.7466015999998,
                "name": "QQQ",
                "close": 691.91998,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.92100485,
                "ma50": 745.0528012400001,
                "name": "SPY",
                "close": 738.16998,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.019675925925926,
          "atrPoints": 2,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140853716,
                "url": "https://finnhub.io/api/news?id=695956b2ab65d68b2b3f676f04a52105e2ab3b5e4a376e3960caa4fd0dc70c9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1783611604,
                "headline": "VTRS or DHR: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 140852441,
                "url": "https://finnhub.io/api/news?id=76b74edca65edcdaf0ee8422d18ecf30575435e589c3a5d0fc58d77584d3dd5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1783604405,
                "headline": "Should Value Investors Buy Viatris (VTRS) Stock?"
              },
              {
                "id": 140818583,
                "url": "https://finnhub.io/api/news?id=faac0612e5716f2b53e9b7b9d846e0387b0426f3ae1660a9ee69596866fb5d24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. recently reported positive Phase 3 results in Japan for VR-205 (Nefecon), an IgA nephropathy treatment, and entered an amended ¥40,000,000,000 senior unsecured term loan agreement with Mizuho Bank to refinance existing debt and support general corporate purposes. The successful VR-205 trial targets a serious kidney disease with high incidence and limited disease-modifying therapies in Japan, positioning Viatris within a clinically important niche of specialty nephrology. We’ll...",
                "category": "company",
                "datetime": 1783328946,
                "headline": "Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?"
              },
              {
                "id": 140815821,
                "url": "https://finnhub.io/api/news?id=610db3331ff00641560bf390ae3fbedccd2c12626bb2733f29ec934988e20348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an […]",
                "category": "company",
                "datetime": 1783291712,
                "headline": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results"
              },
              {
                "id": 140813370,
                "url": "https://finnhub.io/api/news?id=7be707864b28e55a13b967a55b198184f4d4247949396684a27340973787013e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction […]",
                "category": "company",
                "datetime": 1783256653,
                "headline": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140793217,
                "url": "https://finnhub.io/api/news?id=19702475956c2f0e44407ebd7e502e43b82b80ae6c83d80cbe2a1fdd7950a0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1783008003,
                "headline": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?"
              },
              {
                "id": 140704361,
                "url": "https://finnhub.io/api/news?id=b0b5341d803cbe8a4216da13a504d4cf7f8b7a6282ec12ec2818aa6d37f8413e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782229205,
                "headline": "VTRS vs. DHR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140702838,
                "url": "https://finnhub.io/api/news?id=d92a2bba43cd607e76950935c9c1b2c67720c6dfafda9cacb291d5b7e8b0a143",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1782222004,
                "headline": "Are Investors Undervaluing Viatris (VTRS) Right Now?"
              }
            ],
            "raw_source": [
              {
                "id": 140986463,
                "url": "https://finnhub.io/api/news?id=0d5933a5447b91a63d41518b04062f1294db1e80886142b089acd061ad28d640",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Generic drugmakers face U.S. manufacturing deadlines as India and global suppliers weigh potential tariff impact.",
                "category": "company",
                "datetime": 1784750205,
                "headline": "Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%"
              },
              {
                "id": 140984983,
                "url": "https://finnhub.io/api/news?id=7a984fbdc861fe25fe1a43cc59c8e77d35b46db2287536fae3fe4afbffb73899",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.",
                "category": "company",
                "datetime": 1784717109,
                "headline": "Viatris’ Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 140984401,
                "url": "https://finnhub.io/api/news?id=4369f6334decadfe5ab77ef01f15b89812491b70469ba6424682360f7177141b",
                "image": "https://image.cnbcfm.com/api/v1/image/108336351-1784251467141-gettyimages-2285785852-AFP_C2EX37T.jpeg?v=1784251495&w=1920&h=1080",
                "source": "CNBC",
                "related": "VTRS",
                "summary": "Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.",
                "category": "company",
                "datetime": 1784711665,
                "headline": "Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply"
              },
              {
                "id": 140958808,
                "url": "https://finnhub.io/api/news?id=a9f38dfe57dce34baf1fb301ab529faf7cde997e4fdf9d8c53b1bdae9cfa39a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1784546853,
                "headline": "3 Unpopular Stocks We’re Skeptical Of"
              },
              {
                "id": 140936466,
                "url": "https://finnhub.io/api/news?id=60e13162329ea5a02fc22bec12a26041f060c5795c63baefd4143e9360584434",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "JPMorgan Chase stock and two other financial names hit new highs. A pharmaceutical stock also reached a high and is in a buy zone.",
                "category": "company",
                "datetime": 1784317792,
                "headline": "Financial Stocks Rally To New Highs. JPMorgan Is One Of Them."
              },
              {
                "id": 140895823,
                "url": "https://finnhub.io/api/news?id=123e8b50aed0141d75bed0a6810171f383b5f5001acd6792cf43d374ea87737e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2488562/image_2488562.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Organon (OGN) trades below Sun Pharma’s $14 cash bid; assess the 3.7% spread (~6% annualized) and downside risk if it fails—read now.",
                "category": "company",
                "datetime": 1784014459,
                "headline": "Organon & Co: Great Odds, Small Prize, Big Penalty"
              },
              {
                "id": 140898735,
                "url": "https://finnhub.io/api/news?id=5c19ba90558b63a8e3a7afa5519de014d199a61a22aab71804f621e6b3d1ed32",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/2026-To-Be-Far-Worse.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three high-yielding health care stocks: VTRS, MDT, GSK. VTRS to report Q2 results on Aug.6, MDT recalls certain catheter system, GSK reports positive trial results. Benzinga Pro's newsfeed provides real-time alerts.",
                "category": "company",
                "datetime": 1784014208,
                "headline": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 140853716,
                "url": "https://finnhub.io/api/news?id=695956b2ab65d68b2b3f676f04a52105e2ab3b5e4a376e3960caa4fd0dc70c9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1783611604,
                "headline": "VTRS or DHR: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 140852407,
                "url": "https://finnhub.io/api/news?id=93c73432a1e7673d15bfa810df331e53f5a7211080e7837c9bb9d89d1c99a5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'",
                "category": "company",
                "datetime": 1783607460,
                "headline": "Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight"
              },
              {
                "id": 140852441,
                "url": "https://finnhub.io/api/news?id=76b74edca65edcdaf0ee8422d18ecf30575435e589c3a5d0fc58d77584d3dd5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1783604405,
                "headline": "Should Value Investors Buy Viatris (VTRS) Stock?"
              },
              {
                "id": 140832866,
                "url": "https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now",
                "category": "company",
                "datetime": 1783444791,
                "headline": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"
              },
              {
                "id": 140818583,
                "url": "https://finnhub.io/api/news?id=faac0612e5716f2b53e9b7b9d846e0387b0426f3ae1660a9ee69596866fb5d24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. recently reported positive Phase 3 results in Japan for VR-205 (Nefecon), an IgA nephropathy treatment, and entered an amended ¥40,000,000,000 senior unsecured term loan agreement with Mizuho Bank to refinance existing debt and support general corporate purposes. The successful VR-205 trial targets a serious kidney disease with high incidence and limited disease-modifying therapies in Japan, positioning Viatris within a clinically important niche of specialty nephrology. We’ll...",
                "category": "company",
                "datetime": 1783328946,
                "headline": "Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?"
              },
              {
                "id": 140815821,
                "url": "https://finnhub.io/api/news?id=610db3331ff00641560bf390ae3fbedccd2c12626bb2733f29ec934988e20348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an […]",
                "category": "company",
                "datetime": 1783291712,
                "headline": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results"
              },
              {
                "id": 140813370,
                "url": "https://finnhub.io/api/news?id=7be707864b28e55a13b967a55b198184f4d4247949396684a27340973787013e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction […]",
                "category": "company",
                "datetime": 1783256653,
                "headline": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140793217,
                "url": "https://finnhub.io/api/news?id=19702475956c2f0e44407ebd7e502e43b82b80ae6c83d80cbe2a1fdd7950a0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1783008003,
                "headline": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?"
              },
              {
                "id": 140778927,
                "url": "https://finnhub.io/api/news?id=43a21cb0ced81a94cb20a2ab4b974b4cd0c7c93d6aba90a991a99250f77f6e97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss the results.",
                "category": "company",
                "datetime": 1782903540,
                "headline": "Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026"
              },
              {
                "id": 140773043,
                "url": "https://finnhub.io/api/news?id=d350c05ec0fc274e8c6499638c2440b7207f472c50874423fcd02ded7ca7fed2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.",
                "category": "company",
                "datetime": 1782824040,
                "headline": "Theravance Stock Down 3% After Zymeworks Announces Buyout"
              },
              {
                "id": 140760985,
                "url": "https://finnhub.io/api/news?id=3dd1ff9ee83363090b37f246de1973cd2c39f143d5ba8daa89c35977eb3ae750",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease.",
                "category": "company",
                "datetime": 1782730740,
                "headline": "Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy"
              },
              {
                "id": 140764538,
                "url": "https://finnhub.io/api/news?id=f5769a4d0d7ffd22129a63359db792316d4470e59375f3de16f0da3ecca1f1fd",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japanese New Drug",
                "category": "company",
                "datetime": 1782716656,
                "headline": "Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026"
              },
              {
                "id": 140704361,
                "url": "https://finnhub.io/api/news?id=b0b5341d803cbe8a4216da13a504d4cf7f8b7a6282ec12ec2818aa6d37f8413e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782229205,
                "headline": "VTRS vs. DHR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140702838,
                "url": "https://finnhub.io/api/news?id=d92a2bba43cd607e76950935c9c1b2c67720c6dfafda9cacb291d5b7e8b0a143",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1782222004,
                "headline": "Are Investors Undervaluing Viatris (VTRS) Right Now?"
              },
              {
                "id": 140703228,
                "url": "https://finnhub.io/api/news?id=8e79c669503d11407141d135d3ecf2d2ed9737814b31e80a39f5c9b0a2d97468",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220570668/image_2220570668.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline. Click for this VTRS update.",
                "category": "company",
                "datetime": 1782219355,
                "headline": "Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 22,
            "discarded_article_count": 14
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.8,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 9913350,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 9029300,
              "avg_vol_20": 9631530,
              "avg_vol_30": 9913350,
              "range_pct_10": 0.10011574074074076,
              "range_pct_20": 0.10879629629629624,
              "range_pct_30": 0.15856481481481483,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9108222750129875,
              "dist_to_20d_high": 0.02262443438914019,
              "down_shrink_days": 4,
              "breakout_level_20d": 17.68,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6313868613138687
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.019675925925926,
              "turnoverUsdM": 136.66434048000002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VTRS",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 16.2364,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 6,
            "take_profit_price": 18.5358,
            "target_multiplier": 1.9,
            "technical_strength": 1.9,
            "take_profit_percent": 7.3
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2087389804522806,
          "stopLossPercent": 6.039351851851852,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.5218,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.02
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 76.92
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0048
    },
    "kdj": {
      "d": 69.65,
      "j": 76.95,
      "k": 72.08,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 49.17
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 75051816,
      "recentSlope": -157448.4,
      "previousSlope": 1125230
    },
    "rsi": 57.32,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 16.5786,
      "position": "SAR喺價下",
      "distancePct": 4.06,
      "previousTrend": "上升"
    },
    "ma50": 16.3782,
    "macd": {
      "macd": 0.3051669535185013,
      "trend": "強烈看漲",
      "signal": 0.23784984027508546,
      "histogram": 0.06731711324341585
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 16.6518,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 16
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.83,
      "score": 4,
      "avgVolume": 9571721,
      "currentVolume": 7908816
    },
    "derived": {
      "ma20": 16.6645,
      "ma50": 16.3782,
      "prevClose": 17.01,
      "avgVolume10": 8899442,
      "avgVolume20": 9571721,
      "changePercent": 1.59,
      "avgVolumeForScore": 9571721
    },
    "ma_cross": {
      "ma20": 16.6645,
      "ma50": 16.3782,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 16.597,
      "prevMa50": 16.371,
      "spreadPct": 1.75,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 15.7298,
      "upper": 17.5992,
      "position": "上半部"
    },
    "rsi_short": 62.3,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.83
    }
  }
}

{
  "close": 17.28,
  "volume": 7908816,
  "changePercent": 1.59
}